Skip to content

EPS (Diluted) at other companies

CVS Health logo
CVS HealthCVS
$2.30+63.1%
Amazon logo
AmazonAMZN
$2.78+74.8%
Doximity logo
DoximityDOCS
$0.10-67.7%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$0.19+375%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$0.67+379%
Cencora logo
CencoraCOR
$8.40+128%

Other financials

Income statement

See full
Revenue$194.0M-4.4%
Gross profit$173.9M-8.3%
Operating income$14.0M-40.1%
Net income$1.2M-89.4%

Balance sheet

See full
Cash & equivalents$235.7M-21.7%
Total debt$541.4M0.0%
Total equity$622.0M-4.9%
Total assets$2.0B+56.0%

Cash flow

See full
Operating cash flow$11.8M+25.8%
CapEx$1.1M+700%
Free cash flow$10.7M+15.4%

Valuation

See full
Market cap$934.74M-43.1%
Enterprise value$1.24B-34.1%
P/E45.5×-12.3×
P/S1.2×-0.9×

Profitability

See full
Gross margin91.8%-2.0pp
Operating margin9.9%-0.3pp
Net margin2.6%-1.0pp
FCF margin21%+2.3pp

Returns & leverage

See full
Return on equity3.2%-1.2pp
Debt / equity0.9×0.0×
Current ratio1.5×-3.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about GoodRx Holdings, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GoodRx Holdings, Inc.'s EPS (diluted)?
GoodRx Holdings, Inc. (GDRX) reported EPS (diluted) of $0.00 in Q1 2026.
How has GoodRx Holdings, Inc.'s EPS (diluted) changed year-over-year?
GoodRx Holdings, Inc.'s EPS (diluted) decreased by 100.0% year-over-year, from $0.03 to $0.00.
What is the long-term trend for GoodRx Holdings, Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s EPS (diluted) has grown at a 10.7% compound annual growth rate (CAGR), from -$0.06 to $0.09.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.